Two mutations central to the development of infantile myofibromatosis (IM) -- a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers.

Source: Infantile myofibromatosis: First drug targets in childhood genetic tumor disorder